These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 38090576)

  • 21. A second-generation M1-polarized CAR macrophage with antitumor efficacy.
    Lei A; Yu H; Lu S; Lu H; Ding X; Tan T; Zhang H; Zhu M; Tian L; Wang X; Su S; Xue D; Zhang S; Zhao W; Chen Y; Xie W; Zhang L; Zhu Y; Zhao J; Jiang W; Church G; Chan FK; Gao Z; Zhang J
    Nat Immunol; 2024 Jan; 25(1):102-116. PubMed ID: 38012418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy.
    Li N; Geng S; Dong ZZ; Jin Y; Ying H; Li HW; Shi L
    Mol Cancer; 2024 Jun; 23(1):117. PubMed ID: 38824567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAR cell design strategies in solid tumors.
    Wang L; Chen X; Zhang L; Niu B; Li L; Sun Y; Yuan X
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109345. PubMed ID: 36272358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric antigen receptor T cells applied to solid tumors.
    Zhou Z; Tao C; Li J; Tang JC; Chan AS; Zhou Y
    Front Immunol; 2022; 13():984864. PubMed ID: 36389701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.
    Zhang L; Pakmehr SA; Shahhosseini R; Hariri M; Fakhrioliaei A; Karkon Shayan F; Xiang W; Karkon Shayan S
    Med Oncol; 2023 Dec; 41(1):8. PubMed ID: 38062315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma.
    Cai F; Zhang J; Gao H; Shen H
    Eur J Haematol; 2024 Feb; 112(2):223-235. PubMed ID: 37706523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies.
    Zhao D; Zhu D; Cai F; Jiang M; Liu X; Li T; Zheng Z
    Technol Cancer Res Treat; 2023; 22():15330338231204198. PubMed ID: 38037341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanoengineered CAR-T Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal-Remodeling Strategy.
    Chen Z; Pan H; Luo Y; Yin T; Zhang B; Liao J; Wang M; Tang X; Huang G; Deng G; Zheng M; Cai L
    Small; 2021 Apr; 17(14):e2007494. PubMed ID: 33711191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
    Siegler EL; Wang P
    Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.
    Zhang C; Hu Y; Xiao W; Tian Z
    Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.
    Portillo AL; Monteiro JK; Rojas EA; Ritchie TM; Gillgrass A; Ashkar AA
    Front Immunol; 2023; 14():1286750. PubMed ID: 38022679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment.
    Antoñana-Vildosola A; Zanetti SR; Palazon A
    Int Rev Cell Mol Biol; 2022; 370():123-147. PubMed ID: 35798503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors.
    Chen J; Jiang H
    Crit Rev Immunol; 2021; 41(1):1-12. PubMed ID: 33822521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond direct killing-novel cellular immunotherapeutic strategies to reshape the tumor microenvironment.
    Huynh D; Winter P; Märkl F; Endres S; Kobold S
    Semin Immunopathol; 2023 Mar; 45(2):215-227. PubMed ID: 36167831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.
    Bozorgi A; Bozorgi M; Khazaei M
    Cell Oncol (Dordr); 2022 Oct; 45(5):755-777. PubMed ID: 35943716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer Immunotherapies Based on Genetically Engineered Macrophages.
    Cannac M; Nikolic J; Benaroch P
    Cancer Immunol Res; 2022 Oct; 10(10):1156-1166. PubMed ID: 36083784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
    Lindo L; Wilkinson LH; Hay KA
    Front Immunol; 2020; 11():618387. PubMed ID: 33643299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.